Company Filing History:
Years Active: 2002-2013
Title: Innovations by Inventor John D Iuliucci
Introduction
John D Iuliucci is an American inventor based in Andover, MA. He has made significant contributions to the pharmaceutical field, particularly in the development of oral formulations and treatments for bone disorders. With two patents to his name, his work demonstrates a commitment to advancing medical science and improving patient care.
Latest Patents
John's latest patents include groundbreaking innovations in pharmaceutical compositions. One of his notable patents pertains to "Oral formulations," which discloses a solid pharmaceutical composition containing AP23573 that is suitable for oral administration. This formulation aims to enhance the effectiveness and patient compliance in the treatment process. Another significant patent involves "Proton pump inhibitors," providing compounds and methods for treating or preventing severe bone disorders, including osteoporosis, rheumatoid arthritis, and metastatic bone disease. The inventive compounds developed by John feature a bone targeting moiety and a payload that inhibits the proton pump of osteoclasts, thereby effectively reducing bone resorption.
Career Highlights
John currently works at Ariad Pharmaceuticals, Inc., a company known for its innovative approaches in oncology and other therapeutic areas. His work at Ariad has focused on developing formulations that address critical health issues, contributing to significant advancements in patient treatment options.
Collaborations
Throughout his career, John has collaborated with esteemed colleagues, including David C Dalgarno and Manfred Weigele. These partnerships have fostered a collaborative environment that encourages innovation and the exchange of ideas, vital for pushing the boundaries of current medical research.
Conclusion
John D Iuliucci's work exemplifies the transformative impact that inventors can have on healthcare. His patents not only showcase his inventive prowess but also reflect a dedication to addressing complex medical challenges. As he continues his career at Ariad Pharmaceuticals, his future innovations are anticipated to play an essential role in the evolution of pharmaceutical treatments.